Trastuzumab Recruiting Phase 2 Trials for Stage III Colorectal Cancer AJCC v7 / Stage IIIB Colon Cancer AJCC v7 / Recurrent Colorectal Carcinoma / Stage IVA Rectal Cancer AJCC v7 / Stage IIIB Colorectal Cancer AJCC v7 / Stage IVA Colon Cancer AJCC v7 / HER2/Neu Positive / Colorectal Cancers / Stage IIIC Rectal Cancer AJCC v7 / Stage IV Colorectal Cancer AJCC v7 / Stage IIIC Colorectal Cancer AJCC v7 / Metastatic Colon Cancer / Adenocarcinoma of the Colon / Stage IIIA Colon Cancer AJCC v7 / Stage III Colon Cancer AJCC v7 / Stage IVB Rectal Cancer AJCC v7 / Stage IIIA Rectal Cancer AJCC v7 / Recurrent Colon Carcinoma / Stage IIIA Colorectal Cancer AJCC v7 / KRAS wt Allele / ERBB2 Gene Amplification / Adenocarcinoma of the Rectum / Colon Adenocarcinoma / Carcinoma, Colorectal / Stage IIIB Rectal Cancer AJCC v7 / Stage IVA Colorectal Cancer AJCC v7 / NRAS wt Allele / Recurrent Rectal Carcinoma / Stage IVB Colorectal Cancer AJCC v7 / Rectal Adenocarcinoma / HER-2 Gene Amplification / Stage IV Rectal Cancer AJCC v7 / Colorectal Tumors / Colorectal Adenocarcinoma / Stage IIIC Colon Cancer AJCC v7 / Stage III Rectal Cancer AJCC v7 / Stage IVB Colon Cancer AJCC v7 / Metastatic Cancers / Stage IV Colon Cancer AJCC v7 / Neoplasms, Colorectal Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03043313Tucatinib (ONT-380) and Trastuzumab in Treating Patients With HER2+ Metastatic Colorectal Cancer
NCT03365882S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery